As the dust settles on the initial CRISPR and mRNA patent battles, the landscape of IP conflicts in novel therapeutics continues to evolve. This session will bring you up to speed on the latest developments in these high-profile patent wars, while outlining emerging areas of contention within novel therapeutic modalities. Topics of discussion will include:

• Analyzing developments in CRISPR and mRNA patent litigation
• Understanding how these disputes are influencing R&D investments and collaborations
• Identifying new technologies and therapies becoming hotspots for IP litigation, like CRISPR-Cas12 and CRISPR-Cas13, single-cell genomics, bispecific antibodies, and gene silencing therapies
• Devising strategies for navigating the complex patent landscape of novel therapeutics and regenerative medicines
• Understanding how ongoing and potential patent wars could shape the trajectory of novel therapeutics